A Phase 1c Trial Comparing the Efficacy and Safety of a New Aqueous Formulation of Alphaxalone With Propofol

Monagle, John; Siu, Lyndon; Worrell, Jodie; Goodchild, Colin S; Serrao, Juliet M

doi:10.1097/sa.0000000000000210

Cited by 1 publication

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Maintaining arterial blood pressure therefore becomes a goal for developers of new anaesthetics and has already been claimed for alfaxalone reformulated in 7-sulphobutylether beta-cyclodextrin as PhaxanCD™ (Drawbridge Pharmaceuticals, Malvern, VIC, Australia). 13,14…”

Section: Maintaining Systemic Arterial Blood Pressurementioning

confidence: 99%

“…150 In volunteers, PhaxanCD produced a hypnotic effect comparable with that of propofol with less haemodynamic disturbance. 13 Preliminary reports of a small (15 patients) double-blinded comparison with propofol in patients undergoing hip replacement suggest that the favourable characteristics described in volunteers are repeated in patient care. 151…”

Section: Other Novel Hypnotics On the Horizonmentioning

confidence: 99%

See 1 more Smart Citation

Current status of perioperative hypnotics, role of benzodiazepines, and the case for remimazolam: a narrative review

Sneyd

Gambús

Rigby-Jones

2021

British Journal of Anaesthesia

View full text Add to dashboard Cite

Anaesthesiologists and non-anaesthesiologist sedationists have a limited set of available i.v. hypnotics, further reduced by the withdrawal of thiopental in the USA and its near disappearance in Europe. Meanwhile, demand for sedation increases and new clinical groups are using what traditionally are anaesthesiologists' drugs. Improved understanding of the determinants of perioperative morbidity and mortality has spotlighted hypotension as a potent cause of patient harm, and practice must be adjusted to respect this. High-dose propofol sedation may be harmful, and a critical reappraisal of drug choices and doses is needed. The development of remimazolam, initially for procedural sedation, allows reconsideration of benzodiazepines as the hypnotic component of a general anaesthetic even if their characterisation as i.v. anaesthetics is questionable. Early data suggest that a combination of remimazolam and remifentanil can induce and maintain anaesthesia. Further work is needed to define use cases for this technique and to determine the impact on patient outcomes.

show abstract

Section: Maintaining Systemic Arterial Blood Pressurementioning

confidence: 99%

Section: Other Novel Hypnotics On the Horizonmentioning

confidence: 99%